Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olav Dalgard

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Alimentary Pharmacology & Therapeutics|July 6, 2024
Clinical trial: An open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis BAsgeir Johannessen, Dag Henrik Reikvam, Soo Aleman, et al.
Annals of Internal Medicine|August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized TrialGregory J Dore, Frederick Altice, Alain H Litwin, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelMarkus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.
Journal of Internal Medicine|August 19, 2021
Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trialTrine Kåsine, Anne Ma Dyrhol-Riise, Andreas Barratt-Due, et al.
Annals of Internal Medicine|July 12, 2021
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized TrialAndreas Barratt-Due, Inge Christoffer Olsen, Katerina Nezvalova-Henriksen, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Alimentary Pharmacology & Therapeutics|July 6, 2024
Clinical trial: An open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis BAsgeir Johannessen, Dag Henrik Reikvam, Soo Aleman, et al.
Annals of Internal Medicine|August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized TrialGregory J Dore, Frederick Altice, Alain H Litwin, et al.
The International Journal on Drug Policy|July 8, 2017
Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugsJason Grebely, Julie Bruneau, Jeffrey V Lazarus, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2011
A systematic review of hepatitis C virus epidemiology in Europe, Canada and IsraelMarkus Cornberg, Homie A Razavi, Alfredo Alberti, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.
Journal of Internal Medicine|August 19, 2021
Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trialTrine Kåsine, Anne Ma Dyrhol-Riise, Andreas Barratt-Due, et al.
Annals of Internal Medicine|July 12, 2021
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized TrialAndreas Barratt-Due, Inge Christoffer Olsen, Katerina Nezvalova-Henriksen, et al.
Pageof 11